Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Licensing opportunity from NIH: 5-lipoxygenase inhibitors as anticancer agents

Jan. 28, 2000

Novel CDK4 inhibitor series available for licensing from NIH

Jan. 27, 2000

Dendreon initiates patient enrollment in phase III prostate cancer study

Jan. 27, 2000

Eisai team identifies promising new selective RARalpha agonist

Jan. 27, 2000

Enzon describes pegylated prodrugs of antitumor compounds with increased water solubility

Jan. 27, 2000

Phase III results disappointing for marimastat in pancreatic cancer

Jan. 26, 2000

Advanced cancer stabilized by copper-lowering drug in U-M study

Jan. 26, 2000

Angstrom's A6 receives U.S. patent protection; company preparing to begin phase I trials

Jan. 26, 2000

Anticancer and antimetastatic integrin inhibitors in the pipeline at BioChem Pharma

Jan. 26, 2000

Antisense oligonucleotides designed at Isis for modulating PKC expression

Jan. 26, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 14, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...